Pembrolizumab alone and pembrolizumab plus chemotherapy in previously treated, extrapulmonary poorly differentiated neuroendocrine carcinomas

[1]  Wei Peng,et al.  Complete Response to Immunotherapy Combined With Chemotherapy in a Patient With Gynecological Mixed Cancer Mainly Composed of Small Cell Neuroendocrine Carcinoma With High Tumor Mutational Burden: A Case Report , 2022, Frontiers in Oncology.

[2]  L. Seymour,et al.  iRECIST and atypical patterns of response to immuno-oncology drugs , 2022, Journal for ImmunoTherapy of Cancer.

[3]  J. Nemunaitis,et al.  Small-cell breast carcinoma with response to atezolizumab: a case report. , 2022, Immunotherapy.

[4]  A. Sweet-Cordero,et al.  APOBEC Mutational Signature and Tumor Mutational Burden as Predictors of Clinical Outcomes and Treatment Response in Patients With Advanced Urothelial Cancer , 2022, Frontiers in Oncology.

[5]  J. Strosberg,et al.  Efficacy of ipilimumab and nivolumab in patients with high-grade neuroendocrine neoplasms , 2021, ESMO open.

[6]  Chien-Feng Li,et al.  Complete and Durable Response to Nivolumab in Recurrent Poorly Differentiated Pancreatic Neuroendocrine Carcinoma with High Tumor Mutational Burden , 2021, Current oncology.

[7]  E. Polo,et al.  1098O Nivolumab plus platinum-doublet chemotherapy as first-line therapy in unresectable, locally advanced or metastatic G3 neuroendocrine Neoplasms (NENs) of the gastroenteropancreatic (GEP) tract or unknown (UK) origin: Preliminary results from the phase II NICE-NEC trial (GETNE T1913) , 2021, Annals of Oncology.

[8]  P. Nuciforo,et al.  1107P Durvalumab plus tremelimumab in patients with grade 3 neuroendocrine neoplasms of gastroenteropancreatic origin: Updated results from the multicenter phase II DUNE trial (GETNE 1601) , 2021, Annals of Oncology.

[9]  N. Girard,et al.  LBA41 Nivolumab (nivo) ± ipilimumab (ipi) in pre-treated patients with advanced, refractory pulmonary or gastroenteropancreatic poorly differentiated neuroendocrine tumors (NECs) (GCO-001 NIPINEC) , 2021, Annals of Oncology.

[10]  Helen X. Chen,et al.  A phase II basket trial of Dual Anti–CTLA–4 and Anti–PD–1 Blockade in Rare Tumors (DART) SWOG S1609: High‐grade neuroendocrine neoplasm cohort , 2021, Cancer.

[11]  C. Sung,et al.  Comprehensive analysis of mutational and clinicopathologic characteristics of poorly differentiated colorectal neuroendocrine carcinomas , 2021, Scientific Reports.

[12]  A. Fojo,et al.  Novel Tumor Growth Rate Analysis in the Randomized CLARINET Study Establishes the Efficacy of Lanreotide Depot/Autogel 120 mg with Prolonged Administration in Indolent Neuroendocrine Tumors , 2021, The oncologist.

[13]  M. Dominici,et al.  PD-1 blockade in deficient mismatch repair mixed adenoneuroendocrine carcinoma of the stomach: new hope for an orphan disease , 2020, Tumori.

[14]  R. García-Carbonero,et al.  1157O A multi-cohort phase II study of durvalumab plus tremelimumab for the treatment of patients (pts) with advanced neuroendocrine neoplasms (NENs) of gastroenteropancreatic or lung origin: The DUNE trial (GETNE 1601) , 2020 .

[15]  M. Ronot,et al.  Tumor Growth Rate to Predict the Outcome of Patients with Neuroendocrine Tumors: Performance and Sources of Variability , 2020, Neuroendocrinology.

[16]  P. Engstrom,et al.  Pembrolizumab monotherapy in patients with previously treated metastatic high-grade neuroendocrine neoplasms: joint analysis of two prospective, non-randomised trials , 2020, British Journal of Cancer.

[17]  P. Ascierto,et al.  Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized Cohort. , 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[18]  D. Planchard,et al.  Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic Small-Cell Lung Cancer: Results From the KEYNOTE-028 and KEYNOTE-158 Studies. , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[19]  L. Shen,et al.  Hyperprogression after immunotherapy in patients with malignant tumors of digestive system , 2019, BMC Cancer.

[20]  M. Ronot,et al.  Value of Tumor Growth Rate (TGR) as an Early Biomarker Predictor of Patients' Outcome in Neuroendocrine Tumors (NET)-The GREPONET Study. , 2019, The oncologist.

[21]  A. Olshen,et al.  Next-Generation Sequencing of Uveal Melanoma for Detection of Genetic Alterations Predicting Metastasis , 2019, Translational Vision Science & Technology.

[22]  E. Baudin,et al.  Tumor growth rate as a metric of progression, response, and prognosis in pancreatic and intestinal neuroendocrine tumors , 2019, BMC Cancer.

[23]  L. Shen,et al.  Efficacy and safety of PD-1 blockade with JS001 in patients with advanced neuroendocrine neoplasms: A non-randomized, open-label, phase Ib trial. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[24]  H. Sorbye,et al.  Comparative study of lung and extrapulmonary poorly differentiated neuroendocrine carcinomas: A SEER database analysis of 162,983 cases , 2018, Cancer.

[25]  Donavan T. Cheng,et al.  Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology. , 2015, The Journal of molecular diagnostics : JMD.

[26]  W. Hahn,et al.  Prospective enterprise-level molecular genotyping of a cohort of cancer patients. , 2014, The Journal of molecular diagnostics : JMD.

[27]  Kai Ye,et al.  MSIsensor: microsatellite instability detection using paired tumor-normal sequence data , 2014, Bioinform..

[28]  J. Soria,et al.  Tumor growth rate provides useful information to evaluate sorafenib and everolimus treatment in metastatic renal cell carcinoma patients: an integrated analysis of the TARGET and RECORD phase 3 trial data. , 2014, European urology.

[29]  G. Scagliotti,et al.  Extrapulmonary neuroendocrine small and large cell carcinomas: a review of controversial diagnostic and therapeutic issues. , 2014, Human pathology.

[30]  Neelam Gulati,et al.  Assessment of tumor growth in pancreatic neuroendocrine tumors in von Hippel Lindau syndrome. , 2014, Journal of the American College of Surgeons.

[31]  D. Reidy-Lagunes,et al.  The management of extrapulmonary poorly differentiated (high-grade) neuroendocrine carcinomas. , 2013, Seminars in oncology.

[32]  J. Maguire,et al.  Solution Hybrid Selection with Ultra-long Oligonucleotides for Massively Parallel Targeted Sequencing , 2009, Nature Biotechnology.

[33]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.